ENTER IN Orthopaedic Therapies

Products

Biostim^®OsteoSpine^®I-ONE^®Biostim^® SPT OsteoBit^®I-ONE^® TPC FAST^®

Pathologies

Patient Area

Medical Area

Doctor Replies

Scientific Evidence

Electrochemotherapy

ENTER IN Electrochemotherapy

Products

Cliniporator^®Cliniporator^® Vitae Electrodes

Indications

Patient Area

Medical Area

Scientific Evidence and Bibliography

Gene Therapies

ENTER IN Gene Therapies

Products

CLINIPORATOR^® FULL Genedrive Electrodes and Accessories

Nucleic Acid Vaccinations

Research

Scientific Evidence

Company News & Events Research activities Partners Contacts rent or buy

Language

EN IT DE ES

IGEA S.p.A. Via Parmenide, 10/A 41012 Carpi (MO) - Italy tel +39 059 699600 fax +39 059 695778 pec igeamedical.com@pec.it C.F. e P.I. 01021130362 € 168.776,00 i.v. REA 205183 Reg. Soc. Trib. 14968

The Italian Drug Agency Authorizes Clinical Trials of the Italian COVID-eVax Vaccine

Our Electrode E-GUN - Series EPSGun Will Be Used to Administer the Vaccine via Electroporation

Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Drugs Agency (AIFA) of COVID-eVax, the vaccine against COVID-19 designed by Takis and developed in collaboration with Rottapharm Biotech. The Phase I and II clinical trial can now start in February and will provide the first results on safety and immunogenicity about 3 months after the start of the trial.

Unlike other platforms already approved by the European Medicines Agency (EMA) such as mRNA and Adenoviral vectors, COVID-eVax is based on a DNA fragment injected into the muscle that promotes the production of a specific portion of the "Spike” protein, stimulating a strong immune reaction against the virus. The efficiency of the process is increased by the electroporation technique, which favors the passage of DNA inside the cells in a simple, rapid way and without side effects thanks to light and short electrical stimuli.

Discover more

< Back to News and Events

The Italian Drug Agency Authorizes Clinical Trials of the Italian COVID-eVax Vaccine

Our Electrode E-GUN - Series EPSGun Will Be Used to Administer the Vaccine via Electroporation

Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Drugs Agency (AIFA) of COVID-eVax, the vaccine against COVID-19 designed by Takis and developed in collaboration with Rottapharm Biotech. The Phase I and II clinical trial can now start in February and will provide the first results on safety and immunogenicity about 3 months after the start of the trial.

Discover more